Drug development review examining tesamorelin's multiple development programs—including HIV lipodystrophy (phase III), COPD, sleep disorder, hip fracture recovery, immune dysfunction, influenza vaccination, and mild cognitive impairment (all phase II)—covering its mechanism, preclinical profile, and the clinical rationale for each indication. Documents tesamorelin's broad development pipeline. Establishes the therapeutic breadth of tesamorelin's potential applications at the time of phase III development—demonstrating that GHRH-axis stimulation was being explored across aging-related conditions well beyond HIV lipodystrophy, foreshadowing the subsequent clinical investigation of tesamorelin for cognitive impairment and metabolic disease.
Tomlinson, Brian